Connect with us

Biotechnology

Supriya Lifescience Limited (SUPRIYA) breaks below support, moves down 10% intraday

Supriya Lifescience Limited (NSE: SUPRIYA) stock price falls 10% intraday to ₹880.5, breaking below support in a significant breakdown.

Shruti singh - TradeAlone

Published

on

Supriya Lifescience Limited SUPRIYA breaks below support

Supriya Lifescience Limited (SUPRIYA) breaks below support, falling -10% to ₹880.5 on the NSE on 06 Jul 2026. The stock has breached its 6-month support trendline, which was previously at ₹1005.13, signaling a breakdown in the near-term trend. This move comes as the stock was 17% above its 50-day moving average, indicating an extended position. Supriya Lifescience, a key player in the biotechnology sector, has seen its stock react negatively today, potentially due to sector-specific pressures or company-specific factors not immediately clear from the latest NSE filing.

Technical setup — trendlines & DMA

The current trendline structure for Supriya Lifescience shows a breakdown below the 6-month support trendline, which ended at ₹1005.13. The stock is now trading 14.15% below this support level, indicating a significant shift in momentum. Resistance remains at the 6-month resistance trendline end of ₹1229.48, which is 39.63% above the current price. The 50-day moving average (DMA) at ₹834.9 is above the 200-DMA at ₹732.9, suggesting a bullish longer-term trend, though the stock is currently extended above both moving averages. In the 52-week range of ₹545.5 to ₹1085.0, the current price is in the middle third, indicating that while there is room for further downside, a significant portion of the move may already be priced in.

6M Trendline — Intraday Snapshot
BREAKDOWN₹800₹900₹1,00025 May8 Jun22 Jun6 Jul

Snapshot: ₹880.50 on 2026-07-06 (chart frozen at publication)

Fundamentals & business context

With a PE of 37.7, Supriya Lifescience’s valuation appears stretched given its current profit margin of 25.3% and a revenue CAGR of 22.4%. This suggests that the market may be pricing in future growth expectations, though the current earnings may not fully justify the high PE. The company’s institutional holding stands at 4.6%, indicating a relatively low level of interest from institutional investors, which could reflect concerns about the stock’s valuation or growth prospects. There is no specific NSE catalyst today that would explain the move, suggesting that the breakdown may be more technical in nature or related to broader sector sentiment.

SUPRIYA
Holdings Analysis
Key strengths & risk signals
69
Overall
87
Fundamental
52
Technical
Risks (4)
NEGLIGIBLE DIVIDEND! 0.16% yield - little to no income.
POOR YEAR! Stock declined 20.4% in the last year.
WEAK POSITION! Current price (620.1) is below both moving averages.
WEAK! Trading at 13.8% of 52W range - near yearly lows.
Strengths (4)
UNDERVALUED! PEG of 0.87 indicates stock is cheap relative to growth.
BULLISH TREND! 50-day average (841.4) is above 200-day average (787.0) - positive signal.
OVERSOLD! RSI at 24.4 - potential bounce opportunity.
LOW VOLATILITY! Beta of 0.70 - stable stock, less market risk.

Algorithmic scorecard

The overall algorithmic scorecard reflects a technically strong but fundamentally balanced position for Supriya Lifescience. The strongest signals include the company’s excellent revenue and profit CAGRs, which stand at 22.4% and 32.5% respectively, indicating robust growth trends. Additionally, the company’s very low debt levels, with a D/E ratio of 0.01, suggest strong financial health and minimal risk from leverage. On the weaker side, the negligible dividend yield of 0.1% offers little income to shareholders, and the less public holding of 18.43% may limit liquidity and broader market participation. These factors highlight the need for careful consideration of both growth potential and financial stability when evaluating the stock.

Fundamental & Technical AnalysisNSE: SUPRIYA
69Overall
87Fundamental
52Technical
Growth Quality30 / 30
Revenue CAGR: 21.2% (EXCELLENT, 15/15). Profit CAGR: 32.5% (EXCELLENT, 15/15).
Profit Margin8 / 10
EXCELLENT EFFICIENCY! 20.2% profit margin - company keeps strong profits.
PEG Valuation10 / 10
UNDERVALUED! PEG of 0.87 indicates stock is cheap relative to growth.
Dividend Yield3 / 10
NEGLIGIBLE DIVIDEND! 0.16% yield - little to no income.
Debt / Equity10 / 10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding16 / 20
LESS PUBLIC HOLDING! 18.43% public ownership - good institutional/promoter control.
Stability10 / 10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Moving Averages12 / 10
BULLISH TREND! 50-day average (841.4) is above 200-day average (787.0) - positive signal.
Price Position2 / 10
WEAK POSITION! Current price (620.1) is below both moving averages.
Trend Pattern10 / 20
Current trend: CONSOLIDATING DOWN
52W Performance1 / 10
POOR YEAR! Stock declined 20.4% in the last year.
Volume Sentiment15 / 30
BEARISH SENTIMENT! In last 30 days: 11 up days, 19 down days. Avg volume on up days: 419,725 vs down days: 466,704. Ratio: 0.9x
RSI5 / 5
OVERSOLD! RSI at 24.4 - potential bounce opportunity.
52W Range1 / 5
WEAK! Trading at 13.8% of 52W range - near yearly lows.
Momentum1 / 5
NEGATIVE MOMENTUM! Price declined across timeframes - down 1.9% (1 week), 29.0% (1 month), 20.9% (3 months).
Beta / Volatility5 / 5
LOW VOLATILITY! Beta of 0.70 - stable stock, less market risk.

Company outlook

Management has provided a forward-looking guidance of approximately 20% annual growth in revenue and an EBITDA margin target of 33% to 35%. The company remains on track to achieve the INR1,000 crores revenue milestone by FY ’27. However, the annual maintenance shutdown in August is expected to impact revenue growth temporarily. The EBITDA margin is projected to stay within the 33% to 35% range due to product mix and market penetration cycles. On the product front, Supriya Lifescience plans to launch 2 new products in the anesthetics and ADHD portfolios in FY ’27. Additionally, the company is set to begin Phase 1 of the Patalganga facility development in FY ’27, with a capital expenditure of around INR200 crores earmarked for this phase.

Get all details on SUPRIYA — P&L, peers, shareholding and more on TradeAlone.

BIOCON

Biocon Limited (biocon) Secures Marketing Authorization for Pertuzumab in EU

Biocon Limited (BIOCON) secures EU marketing authorization for Pertuzumab, its first biosimilar under new clinical approach.

abhinav tiwari

Published

on

Biocon Limited Biocon November 2026 Event

Biocon Limited (BSE: 532523; NSE: BIOCON) has announced that the European Commission (EC) has granted marketing authorization for Pebrilzo®, its biosimilar pertuzumab, for the treatment of HER2-positive breast cancer across multiple disease stages in the European Union (EU). This marks a significant regulatory milestone for Biocon, as pertuzumab becomes its fifth oncology biosimilar approved in both Europe and the United States, strengthening its global oncology portfolio.

First Biosimilar Under New Clinical Approach

Biocon’s pertuzumab biosimilar is the first biosimilar to receive EC marketing authorization under the European Medicines Agency’s (EMA) new tailored clinical approach. This milestone follows its positive CHMP opinion on September 17, 2026. Shreehas Tambe, CEO & Managing Director, Biocon, said: “The European Commission’s approval of Pebrilzo®, our pertuzumab biosimilar, the first under its new tailored clinical pathway, marks a significant regulatory milestone for Biocon. With this approval, pertuzumab becomes our fifth oncology biosimilar approved in both Europe and the United States, strengthening our global oncology portfolio and reinforcing our commitment to expanding access to high-quality, affordable biologic therapies for patients with HER2-positive breast cancer.”

Broadening Treatment Options

The approval aims to broaden treatment options for patients with HER2-positive breast cancer while supporting more sustainable healthcare systems in Europe. Extensive orthogonal, state-of-the-art structural and functional analytical characterization, together with comparative clinical pharmacokinetic data, demonstrated that Biocon’s pertuzumab biosimilar is highly similar to the reference product, with no clinically meaningful differences in quality, safety, or efficacy.

As Biocon continues to expand its portfolio and commitment to oncology, this approval underscores its dedication to addressing evolving patient and healthcare needs, particularly in the realm of breast cancer treatment.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Biocon Limited

Biocon Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

BIOCON
Healthcare › Biotechnology
CONSOLIDATING DOWN
52
Fundamental
56
Technical
55
Overall

1W +0.1%
1M +7.18%
3M -11.55%
P/E: 122.3 Cap: Large
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Biocon falls 12.8% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock gains 2.9% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 15.3% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Biocon Limited.

Continue Reading

Biotechnology

Dishman Carbogen Amcis Limited (dcal) Q2fy27 Results: Revenue Down 22.8% Yoy

Dishman Carbogen Amcis Limited (NSE: DCAL) reports Q2FY27 results with a 22.8% YoY revenue decline, driven by lower CDMO segment revenue.

Deputy Editor, Equities for tradealone

Published

on

Dishman Carbogen Amcis Limited DCAL Q2fy27 Results

Dishman Carbogen Amcis Limited (NSE: DCAL) has released its financial results for the second quarter of FY27, ending September 30, 2026. The company reported a net revenue of ₹ 6,527 million for Q2FY27, marking a 22.8% year-on-year decline compared to ₹ 8,463 million in Q2FY26. This decline is primarily attributed to lower revenue from the Contract Development and Manufacturing Organisation (CDMO) segment.

Key Financial Highlights

The EBITDA margin for Q2FY27 stood at 9.1%, significantly lower than the 22.8% recorded in the same quarter of the previous fiscal year. The EBITDA for Q2FY27 was ₹ 459.6 million, a sharp decrease from ₹ 1,488.9 million in Q2FY26. The company’s EBITDA margin for the first half of FY27 was 8.9%, down from 21.3% in H1FY26.

Segment Performance

The CDMO segment revenue for Q2FY27 was ₹ 3,887.5 million, a 23.7% decrease from ₹ 5,094.0 million in Q2FY26. The decline is mainly due to lower development revenue and the rescheduling of project deliverables worth approximately CHF 10 million to H2FY27. On the other hand, the marketable molecules segment revenue increased by 6.6% year-on-year to ₹ 1,186.2 million, supported by higher sales of Quaternary compounds.

However, the overall revenue for H1FY27 was ₹ 11,805 million, down 12.9% compared to ₹ 13,607 million in H1FY26. The CDMO segment revenue for H1FY27 was ₹ 9,290.4 million, a 17.1% decrease from ₹ 11,206.4 million in H1FY26, primarily due to lower development revenue. The marketable molecules segment revenue for H1FY27 was ₹ 2,559.7 million, up 2.4% from ₹ 2,400.6 million in H1FY26, driven by higher sales of Quaternary compounds.

As a result, the company’s net profit after tax (PAT) for Q2FY27 was a loss of ₹ 667.3 million, compared to a profit of ₹ 652.7 million in Q2FY26. For H1FY27, the PAT was a loss of ₹ 1,246.1 million, compared to a profit of ₹ 886.8 million in H1FY26.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Dishman Carbogen Amcis Limited

Dishman Carbogen Amcis Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

DCAL
Healthcare › Biotechnology
CONSOLIDATING DOWN
52
Fundamental
34
Technical
43
Overall

1W -33.17%
1M -20.73%
3M -34.27%
P/E: 112.2 Cap: Small
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Dishman falls 9.3% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. 2 loss quarter(s) over five years signals earnings fragility — not chronic but worth noting. The stock gains 13.0% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Price climbs recently despite 7.5% revenue growth and a PEG of 99.00. Consequently, either institutions position ahead of improvement or the move fades when earnings disappoint. Treat this as a trading signal, not an investment thesis. Check Fundamentals of Dishman Carbogen Amcis Limited.

Continue Reading

BIOCON

Biocon Limited Gets U.S. FDA Approval for Pebrilzo™ (pertuzumab-qcay) Injection

Biocon Limited (BIOCON) receives U.S. FDA approval for Pebrilzo™ (pertuzumab-qcay), a biosimilar to Perjeta®, expanding its oncology portfolio.

kuldeep yadav tradealone

Published

on

Biocon Limited Biocon FDA Approval Pebrilzo

Biocon Limited (BIOCON) announced today that the U.S. Food and Drug Administration (FDA) has approved Pebrilzo™ (pertuzumab-qcay), a biosimilar of the reference product Perjeta®. This marks another significant milestone in Biocon’s journey to expand access to high-quality biosimilars. Pebrilzo™ is a monoclonal antibody used to treat HER2-positive breast cancer by blocking HER2 receptors on cancer cells. The FDA approval further strengthens Biocon’s oncology portfolio, now totaling five biosimilar therapies for cancer in the United States.

Expanding Access to Affordable Biologics

Shreehas Tambe, CEO & Managing Director, Biocon Limited, said, “The U.S. FDA approval of Pebrilzo™, our biosimilar pertuzumab, marks another significant milestone in Biocon’s journey to expand access to high-quality biosimilars. For patients diagnosed with HER2-positive breast cancer, the burden of the disease extends well beyond the physical challenges, often placing considerable financial strain on patients and their families. As our fifth oncology biosimilar to receive U.S. FDA approval, Pebrilzo™ strengthens our anti-cancer portfolio and advances our commitment to expanding access to high-quality, affordable biologic medicines.”

Strengthening Oncology Portfolio

Pebrilzo™ will join Biocon’s robust portfolio of oncology therapies, which includes Ogivri® (trastuzumab-dkst), Jobevne® (bevacizumab-nwgd), Fulphila® (pegfilgrastim-jmdb), and Aukelso® (denosumab-kyqq). Building on this foundation, Biocon’s growing oncology pipeline includes proposed biosimilars to trastuzumab/hyaluronidase, nivolumab, and pembrolizumab, spanning HER2-directed therapy and immuno-oncology.

As a result, Biocon’s oncology strategy combines an established portfolio with continued development across additional treatment approaches, addressing the ongoing need for treatment options in this area.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Biocon Limited

Biocon Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

BIOCON
Healthcare › Biotechnology
CONSOLIDATING DOWN
52
Fundamental
56
Technical
55
Overall

1W +0.1%
1M +7.18%
3M -11.55%
P/E: 122.3 Cap: Large
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Biocon falls 12.7% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock gains 3.8% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 15.3% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Biocon Limited.

Continue Reading

Trending

Exit mobile version